GeneSight Mental Health Monitor Media Kit: Symptoms of Depression
New research reveals most Americans can’t identify the symptoms of depression
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression
SALT LAKE CITY, July 28, 2021 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.
The GeneSight Mental Health Monitor is a nationwide survey conducted by ACUPOLL Precision Research, Inc. during Aug.-Sept. 2021 among a statistically representative sample of adults age 21+, including a representative sample diagnosed with anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.